Dronabinol Capsule
Product Images NDC 31722-961

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dronabinol (NDC 31722-961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 (10 mg)

Dronabinol Capsules, USP 10 mg oral capsules label from Camber Pharmaceuticals Inc. The label indicates a package count of 60 capsules, marked Rx only. It includes storage instructions and manufacturer information, with a lot and expiration date box and a barcode on the left side.*

FDA Label Image

2.5 (2.5 mg)

Label for DRONABINOL Capsules, USP 2.5 mg oral capsules by Camber Pharmaceuticals Inc. The label states the package contains 60 capsules and includes handling and storage instructions, manufacturer information, and a barcode. It specifies the drug is Rx only and includes the NDC number 31722-960-60.*

FDA Label Image

5 (5 mg)

Label for DRONABINOL Capsules, USP 5 mg oral capsules by Camber Pharmaceuticals Inc. The packaging indicates 60 capsules per container, with a barcode and storage instructions. It includes manufacturer information for Camber Pharmaceuticals and Ascent Pharmaceuticals, and a warning to not accept if the bottle seal is broken or missing.*

FDA Label Image

Abs (Dronabinol Absorption)

A data table summarizing multiple-dose pharmacokinetic parameters of dronabinol in healthy subjects aged 20-45 under fasted conditions. It shows mean and standard deviation values for Cmax (maximum plasma concentration), median Tmax (time to maximum plasma concentration), and AUC0-12 (area under the plasma concentration-time curve from 0 to 12 hours) at twice daily doses of 2.5 mg, 5 mg, and 10 mg.*

FDA Label Image

Fig1 (Dronabinol Figure1)

A line graph titled 'Mean Appetite Change from Baseline' comparing dronabinol 2.5 mg BID to placebo over 6 weeks. The vertical axis measures appetite change in mm VAS, and the horizontal axis shows time in weeks. The dronabinol group shows a steady increase in appetite, significantly higher than placebo at 4 and 6 weeks (p-value <0.05).*

FDA Label Image

Rc (Dronabinol Rc)

A text panel listing potential side effects or adverse reactions of a drug, including dizziness, euphoria, paranoia, sleepiness, abnormal thoughts, abdominal pain, nausea, and vomiting. No specific drug name or dosage is visible in this section.*

FDA Label Image

Struct (Dronabinol Struct)

Chemical structure diagram of dronabinol, the active ingredient in DRONABINOL capsules by Camber Pharmaceuticals Inc. The structure shows the molecular arrangement including hydroxyl, methyl, and alkyl groups characteristic of dronabinol.*

FDA Label Image

Adr (Dronabinol Adv)

Data tables listing common and less common adverse reactions reported in clinical trials for dronabinol capsules. The tables categorize adverse reactions by system organ class, showing symptoms with incidences greater than 1% and those with incidences less than or equal to 1%. Common reactions include asthenia, palpitations, gastrointestinal symptoms, and central nervous system effects such as dizziness and euphoria. Less common reactions include chills, hypotension, diarrhea, depression, respiratory issues, flushing, and vision difficulties.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.